Please login or register to print this page.

Clinical Articles

Positive NICE Final Appraisal For Dronedarone

The National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal determination on dronedarone (Multaq) recommending the drug as an option for non-permanent atrial fibrillation (AF) in selected patients. (1)

Dronedarone can be prescribed as a second-line treatment in

those people with non-permanent AF patients whose AF is not controlled by first-line therapy (usually including beta blockers) and who have at least one of the following risk factors:

  • Hypertension requiring 2 drugs of at least 2 different classes
  • Diabetes mellitus
  • Previous transient attack (TIA), stroke or systemic embolism
  • Left atrial diameter ≥50 mm
  • Left ventricular ejection fraction <40% (dronedarone not recommended for  those with LVEF <35%) or age 70 years or more and who do not have unstable New York Heart Association (NYHA) class III or IV heart failure.

People who do not meet these criteria, who are currently receiving dronedarone should have the option to continue treatment until they or their clinicians consider it appropriate to stop.

The recommendations from NICE have been broadly welcomed. They follow a sustained campaign by cardiologists and other healthcare professionals (HCP) along with the Arrhythmia Alliance to have dronedarone available for prescription with NHS funding.

A new website, www.multaq.co.uk is available for HCPs, which has specific section for patients, and carries general information about atrial fibrillation and Multaq in particular.

Reference

Published on: July 22, 2010

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.